Last reviewed · How we verify

biological monitoring

University of Roma La Sapienza · FDA-approved active Biologic Quality 2/100

biological monitoring is a Biologic drug developed by University of Roma La Sapienza. It is currently FDA-approved.

Biological monitoring, developed by the University of Roma La Sapienza, is a marketed product with a key composition patent expiring in 2028. The primary strength of this drug lies in its established market presence, leveraging the university's research expertise. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namebiological monitoring
SponsorUniversity of Roma La Sapienza
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about biological monitoring

What is biological monitoring?

biological monitoring is a Biologic drug developed by University of Roma La Sapienza.

Who makes biological monitoring?

biological monitoring is developed and marketed by University of Roma La Sapienza (see full University of Roma La Sapienza pipeline at /company/university-of-roma-la-sapienza).

What development phase is biological monitoring in?

biological monitoring is FDA-approved (marketed).

Related